Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Juergen Froehlich"'
Autor:
Bruce Thompson, Adam Wanner, Anne E. O'Donnell, James D. Chalmers, Juergen Froehlich, Igor Gonda, Charles S. Haworth, Angela Davis, Diana Bilton
Publikováno v:
The Lancet Respiratory Medicine. 7:213-226
Summary Background In patients with non-cystic fibrosis bronchiectasis, lung infection with Pseudomonas aeruginosa is associated with frequent pulmonary exacerbations and admission to hospital for treatment, reduced quality of life, and increased mor
Autor:
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
Publikováno v:
Respiratory infections.
Publikováno v:
C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT.
Autor:
J. Dahms, Juergen Froehlich, D.R. VanDevanter, James D. Chalmers, Igor Gonda, David Cipolla, Angela Davis
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 25(12)
Objectives Non-cystic fibrosis bronchiectasis (NCFBE) with Pseudomonas aeruginosa has been associated with increased pulmonary exacerbation (PEx) and mortality risk. European Respiratory Society guidelines conditionally recommend inhaled antimicrobia
Autor:
Gregory Tino, James D. Chalmers, David Cipolla, Anne E. O'Donnell, Juergen Froehlich, Igor Gonda, Bruce Thompson, Angela Davis, Charles S. Haworth
Publikováno v:
European Respiratory Journal. 56:2000110
It is not known if inhaled antibiotics improve respiratory symptoms in patients with bronchiectasis. In the recent phase-3 ORBIT trials, 48 weeks' treatment with ARD-3150 (inhaled liposomal ciprofloxacin) did not significantly improve symptoms using
Autor:
Juergen Froehlich, David Cipolla, Bruce Thompson, Anne E. O'Donnell, Janice Dahms, Charles S. Haworth, Angela Davis, Igor Gonda
Publikováno v:
Respiratory infections.
Introduction: ARD-3150 is a once-daily inhaled formulation of liposomal and free ciprofloxacin tested in two 48 week randomized (2:1) placebo controlled Phase 3 trials (ORBIT-3 and ORBIT-4) in NCFB patients with chronic PA lung infections. Pulmonary
Autor:
Angela Davis, David Cipolla, Charles S. Haworth, Igor Gonda, Juergen Froehlich, Anne E. O'Donnell
Publikováno v:
Respiratory infections.
Introduction: ARD-3150 (ARD) is a once-daily 6 mL nebulized formulation of liposomal (135 mg) and free (54 mg) ciprofloxacin that was tested in two 48-week phase 3 trials (ORBIT-3 [NCT01515007]; ORBIT-4 [NCT02104245]) in NCFB patients with chronic P.
Autor:
Anne E. O'Donnell, Adam Wanner, Angela Davis, Charles S. Haworth, Bruce Thompson, Juergen Froehlich, James D. Chalmers, Diana Bilton, Igor Gonda
Publikováno v:
SSRN Electronic Journal.
Background: In patients with non-cystic fibrosis bronchiectasis (NCFB), lung infection with Pseudomonas aeruginosa is associated with severe disease, frequent pulmonary exacerbations (PEs) and hospitalisations, reduced quality of life, and higher mor
The second edition of the book begins with the description of the diversity of wine-related microorganisms, followed by an outline of their primary and energy metabolism. Subsequently, important aspects of the secondary metabolism are dealt with, sin
Publikováno v:
Respiratory Infections.
Background: Patients (pts) with NCFB and chronic PA may have resistant isolates owing to frequent antibiotic use. High inhaled antibiotic concentrations in sputum may overcome resistance. In a post-hoc analysis of ARD-3150 treated pts from 2 identica